JP2023504147A5 - - Google Patents
Info
- Publication number
- JP2023504147A5 JP2023504147A5 JP2022532148A JP2022532148A JP2023504147A5 JP 2023504147 A5 JP2023504147 A5 JP 2023504147A5 JP 2022532148 A JP2022532148 A JP 2022532148A JP 2022532148 A JP2022532148 A JP 2022532148A JP 2023504147 A5 JP2023504147 A5 JP 2023504147A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- use according
- compound
- cancer
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025207457A JP2026048713A (ja) | 2019-12-04 | 2025-11-28 | ユビキチンプロテオソーム経路を介したｂｔｋの分解のための二官能性化合物 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962943720P | 2019-12-04 | 2019-12-04 | |
| US62/943,720 | 2019-12-04 | ||
| US202063010524P | 2020-04-15 | 2020-04-15 | |
| US63/010,524 | 2020-04-15 | ||
| PCT/US2020/063176 WO2021113557A1 (en) | 2019-12-04 | 2020-12-03 | Bifunctional compounds for degrading btk via ubiquitin proteosome pathway |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025207457A Division JP2026048713A (ja) | 2019-12-04 | 2025-11-28 | ユビキチンプロテオソーム経路を介したｂｔｋの分解のための二官能性化合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023504147A JP2023504147A (ja) | 2023-02-01 |
| JP2023504147A5 true JP2023504147A5 (enExample) | 2023-12-05 |
Family
ID=74004152
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022532148A Pending JP2023504147A (ja) | 2019-12-04 | 2020-12-03 | ユビキチンプロテオソーム経路を介したｂｔｋの分解のための二官能性化合物 |
| JP2025207457A Pending JP2026048713A (ja) | 2019-12-04 | 2025-11-28 | ユビキチンプロテオソーム経路を介したｂｔｋの分解のための二官能性化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025207457A Pending JP2026048713A (ja) | 2019-12-04 | 2025-11-28 | ユビキチンプロテオソーム経路を介したｂｔｋの分解のための二官能性化合物 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US11820781B2 (enExample) |
| EP (2) | EP4570320A3 (enExample) |
| JP (2) | JP2023504147A (enExample) |
| KR (1) | KR102998007B1 (enExample) |
| CN (1) | CN115003304A (enExample) |
| AU (2) | AU2020397920B2 (enExample) |
| BR (1) | BR112022010349A2 (enExample) |
| CA (1) | CA3160713A1 (enExample) |
| DK (1) | DK4069237T3 (enExample) |
| ES (1) | ES3033520T3 (enExample) |
| FI (1) | FI4069237T3 (enExample) |
| HU (1) | HUE072392T2 (enExample) |
| IL (1) | IL293797A (enExample) |
| MX (1) | MX2022006672A (enExample) |
| PL (1) | PL4069237T3 (enExample) |
| WO (1) | WO2021113557A1 (enExample) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3867242A1 (en) | 2018-10-15 | 2021-08-25 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading btk via ubiquitin proteosome pathway |
| US12509455B2 (en) | 2018-11-07 | 2025-12-30 | Dana-Farber Cancer Institute, Inc. | Imidazopyridine derivatives and aza-imidazopyridine derivatives as Janus kinase 2 inhibitors and uses thereof |
| WO2020097396A1 (en) | 2018-11-07 | 2020-05-14 | Dana-Farber Cancer Institute, Inc. | Benzimidazole derivatives and aza-benzimidazole derivatives as janus kinase 2 inhibitors and uses thereof |
| EP3876939A4 (en) | 2018-11-07 | 2022-08-10 | Dana-Farber Cancer Institute, Inc. | Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof |
| WO2020160295A1 (en) | 2019-01-30 | 2020-08-06 | Montelino Therapeutics, Llc | Bi-functional compounds and methods for targeted ubiquitination of androgen receptor |
| EP3924350A1 (en) | 2019-02-13 | 2021-12-22 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading btk via ubiquitin proteosome pathway |
| EP3932922A4 (en) | 2019-02-25 | 2022-05-11 | ShanghaiTech University | SULPHUR-CONTAINING COMPOUND BASED ON A GLUTARIMIDE FRAMEWORK AND ITS USE |
| KR102922115B1 (ko) | 2019-04-09 | 2026-02-04 | 누릭스 테라퓨틱스 인코포레이티드 | Cbl-b 억제용의 3-치환된 피페리딘 화합물, 및 암 백신 및/또는 종양용해 바이러스와 조합된 cbl-b 억제제의 용도 |
| CA3140873A1 (en) | 2019-05-17 | 2020-11-26 | Nurix Therapeutics, Inc. | Cyano cyclobutyl compounds for cbl-b inhibition and uses thereof |
| CA3294689A1 (en) | 2019-06-26 | 2026-03-02 | Nurix Therapeutics, Inc. | Substituted benzyl-triazole compounds for cbl-b inhibition, and further uses thereof |
| US12653809B2 (en) | 2019-07-30 | 2026-06-16 | Nurix Therapeutics, Inc. | Urea, amide, and substituted heteroaryl compounds for CBL-B inhibition |
| WO2021023233A1 (zh) | 2019-08-05 | 2021-02-11 | 上海科技大学 | Egfr蛋白降解剂及其抗肿瘤应用 |
| EP4034141A1 (en) | 2019-09-24 | 2022-08-03 | Nurix Therapeutics, Inc. | Cbl inhibitors and compositions for expansion of immune cells |
| CA3156828A1 (en) | 2019-10-03 | 2021-04-08 | Dana-Farber Cancer Institute, Inc. | Tricyclic kinase inhibitors and uses thereof |
| CA3160713A1 (en) | 2019-12-04 | 2021-06-10 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading btk via ubiquitin proteosome pathway |
| JP7815127B2 (ja) | 2020-02-19 | 2026-02-17 | ニューリックス セラピューティクス，インコーポレイテッド | インターロイキン－１受容体関連キナーゼの二機能性分解剤およびその治療的使用 |
| AU2021226514B2 (en) * | 2020-02-25 | 2023-10-19 | Shanghaitech University | Glutarimide skeleton-based compounds and application thereof |
| TW202204350A (zh) | 2020-05-06 | 2022-02-01 | 美商雅捷可斯治療公司 | 作為ｊａｋ２抑制劑之６－雜芳基氧基苯并咪唑及氮雜苯并咪唑 |
| EP4267574B1 (en) | 2020-12-23 | 2025-04-23 | Ajax Therapeutics, Inc. | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors |
| US12016860B2 (en) | 2021-04-08 | 2024-06-25 | Nurix Therapeutics, Inc. | Combination therapies with Cbl-b inhibitor compounds |
| MX2023012981A (es) * | 2021-05-03 | 2024-01-11 | Nurix Therapeutics Inc | Compuestos para inhibir o degradar proteinas objetivo, composiciones que los comprenden, metodos para su preparacion y metodos para usarlos. |
| CA3217792A1 (en) | 2021-05-07 | 2022-11-10 | Kymera Therapeutics, Inc | Cdk2 degraders and uses thereof |
| KR20240026946A (ko) * | 2021-06-25 | 2024-02-29 | 셀진 코포레이션 | 세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법 |
| KR20240029070A (ko) * | 2021-07-01 | 2024-03-05 | 항저우 힐젠 테라퓨틱스 컴퍼니 리미티드 | 브루톤 티로신 키나아제, 이의 돌연변이체 분해제, 조성물 및 응용 |
| IL309796A (en) | 2021-07-14 | 2024-02-01 | Nurix Therapeutics Inc | Bifunctional compounds for BTK degradation with reduced IMID activity |
| EP4373493A1 (en) | 2021-07-23 | 2024-05-29 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading btk with enhanced imid activity |
| WO2023009709A1 (en) * | 2021-07-29 | 2023-02-02 | Ajax Therapeutics, Inc. | Pyrazolo piperazines as jak2 inhibitors |
| HUE070709T2 (hu) | 2021-08-18 | 2025-06-28 | Nurix Therapeutics Inc | Interleukin-1 receptorhoz kapcsolódó kinázok kétfunkciós lebontói és terápiás alkalmazásuk |
| CA3231240A1 (en) * | 2021-09-08 | 2023-03-16 | Sarat CHANDARLAPATY | Ink4 tumor suppressor proteins mediate resistance to cdk4/6 kinase inhibitors |
| US20240317734A1 (en) * | 2021-09-13 | 2024-09-26 | Montelino Therapeutics, Inc. | Bi-functional compounds and methods for targeted ubiquitination of androgen receptor |
| WO2023059582A1 (en) * | 2021-10-04 | 2023-04-13 | Halda Therapeutics Opco, Inc. | Heterobifunctional compounds and their use in treating disease |
| MX2024004899A (es) * | 2021-10-26 | 2024-05-24 | Nurix Therapeutics Inc | Compuestos de piperidinilpirazina-carboxamida para tratar y prevenir el cancer y para degradar btk. |
| US12162881B2 (en) | 2021-11-09 | 2024-12-10 | Ajax Therapeutics, Inc. | Forms and compositions of inhibitors of JAK2 |
| CA3234638A1 (en) | 2021-11-09 | 2023-05-19 | Ajax Therapeutics, Inc. | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors |
| CN119823111B (zh) * | 2021-11-18 | 2026-05-05 | 正大天晴药业集团股份有限公司 | 稠合酰亚胺类衍生物 |
| CN118598858A (zh) | 2021-11-22 | 2024-09-06 | 杭州和正医药有限公司 | 一种可降解btk激酶的多功能化合物、组合物及应用 |
| AU2022405474B2 (en) * | 2021-12-08 | 2026-08-13 | Gluetacs Therapeutics (Shanghai) Co., Ltd. | E3 ubiquitin ligase ligand compound, protein degrader developed based thereon and their applications |
| KR20250020448A (ko) | 2022-06-02 | 2025-02-11 | 시젱 하이스코 파마수티칼 씨오., 엘티디. | Bcl6을 억제하거나 분해하는 화합물 및 의약학에서의 응용 |
| WO2023239629A1 (en) | 2022-06-06 | 2023-12-14 | Plexium, Inc. | Compounds and pharmaceutical compositions that degrade cdk2 |
| CN117384161A (zh) * | 2022-07-04 | 2024-01-12 | 华东理工大学 | 靶向降解cdk蛋白的化合物及其应用 |
| KR20250037565A (ko) * | 2022-07-25 | 2025-03-17 | 셀진 코포레이션 | Irak3의 리간드 지정 분해제로서의 치환된 이미다조피라진 화합물 |
| EP4578849A4 (en) * | 2022-08-26 | 2025-11-26 | Fujifilm Corp | NEW PIPERAZINE DERIVATIVE OR SALT THEREOF AND PHARMACEUTICAL COMPOSITION |
| WO2024102970A1 (en) * | 2022-11-11 | 2024-05-16 | Kronos Bio, Inc. | Compounds for modulating syk activity and e3 ubiquitin ligase activity |
| EP4759807A1 (en) | 2023-08-11 | 2026-06-17 | Shenzhen Zhongge Biological Technology Co., Ltd. | Proteolysis targeting chimera compound for degrading irak4 and use thereof |
| WO2025085738A1 (en) | 2023-10-18 | 2025-04-24 | Halda Therapeutics Opco, Inc. | Heterobifunctional compounds and methods of treating disease |
| CN122514523A (zh) * | 2023-10-23 | 2026-08-04 | 纽力克斯治疗公司 | 双官能化合物的盐和游离碱及其多晶型物形式 |
| WO2025162210A1 (zh) | 2024-02-04 | 2025-08-07 | 上海超阳药业有限公司 | 一种具备降解酪氨酸蛋白激酶btk活性的化合物及其制备方法和用途 |
| WO2025174220A1 (ko) * | 2024-02-14 | 2025-08-21 | 주식회사 유빅스테라퓨틱스 | Shp2 단백질 분해 활성을 갖는 화합물 및 이들의 의약 용도 |
| WO2025189056A1 (en) | 2024-03-08 | 2025-09-12 | Halda Therapeutics Opco, Inc. | Heterobifunctional compounds and their use in treating disease |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004099388A2 (en) | 2003-03-05 | 2004-11-18 | Proteologics, Inc. | Cbl-b polypeptides, complexes and related methods |
| WO2007072225A2 (en) | 2005-12-01 | 2007-06-28 | Medical Prognosis Institute | Methods and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy |
| WO2008033403A2 (en) | 2006-09-13 | 2008-03-20 | The Trustees Of Columbia University In The City Of New York | Agents and methods to elicit anti-tumor immune response |
| AT506041A1 (de) | 2007-12-10 | 2009-05-15 | Univ Innsbruck | Verfahren zur erhöhung der immunreaktivität |
| ES2420846T3 (es) | 2008-02-05 | 2013-08-27 | F. Hoffmann-La Roche Ag | Nuevas piridinonas y piridazinonas |
| CN102458402B (zh) | 2009-06-12 | 2013-10-02 | 百时美施贵宝公司 | 用作激酶调节剂的烟酰胺化合物 |
| CA3034600C (en) | 2010-05-07 | 2020-11-10 | Genentech, Inc. | Pyridone and aza-pyridone compounds and methods of use |
| AR082590A1 (es) | 2010-08-12 | 2012-12-19 | Hoffmann La Roche | Inhibidores de la tirosina-quinasa de bruton |
| EP2471548A1 (de) | 2010-12-28 | 2012-07-04 | Apeiron Biologics AG | siRNA gegen Cbl-b und optional IL2 und IL12 zur Verwendung in der Behandlung von Krebs |
| US20130110678A1 (en) | 2011-11-02 | 2013-05-02 | Apple Inc. | Purchasing a product in a store using a mobile device |
| UA111756C2 (uk) | 2011-11-03 | 2016-06-10 | Ф. Хоффманн-Ля Рош Аг | Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона |
| US8669251B2 (en) | 2011-11-03 | 2014-03-11 | Genentech, Inc. | 8-fluorophthalazin-1(2H)-one compounds |
| KR102438072B1 (ko) | 2012-01-12 | 2022-08-31 | 예일 유니버시티 | E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법 |
| US9499548B2 (en) | 2012-09-13 | 2016-11-22 | Hoffmann-La Roche Inc. | Inhibitors of bruton's tyrosine kinase |
| US10308707B2 (en) | 2013-12-02 | 2019-06-04 | Aaron Diamond Aids Research Center | Bispecific HIV-1-neutralizing antibodies |
| AU2014360446A1 (en) * | 2013-12-05 | 2016-06-09 | Pharmacyclics, Llc | Inhibitors of Bruton's tyrosine kinase |
| GB201506871D0 (en) * | 2015-04-22 | 2015-06-03 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| BR112017025986A2 (pt) | 2015-06-02 | 2018-08-14 | Pharmacyclics Llc | inibidores de tirosina quinase de bruton. |
| CN108026088B (zh) | 2015-07-17 | 2021-02-12 | 武田药品工业株式会社 | 用作hdac抑制剂的噁二唑衍生物 |
| GB201614134D0 (en) * | 2016-08-18 | 2016-10-05 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| CN110099998A (zh) | 2016-10-26 | 2019-08-06 | 艾欧凡斯生物治疗公司 | 冷冻保存的肿瘤浸润淋巴细胞的再刺激 |
| TWI788307B (zh) | 2016-10-31 | 2023-01-01 | 美商艾歐凡斯生物治療公司 | 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞 |
| US10842878B2 (en) * | 2016-11-22 | 2020-11-24 | Dana-Farber Cancer Institute, Inc. | Degradation of Bruton's tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand and methods of use |
| CA3045037A1 (en) * | 2016-12-08 | 2018-06-14 | Icahn School Of Medicine At Mount Sinai | Compositions and methods for treating cdk4/6-mediated cancer |
| JOP20190224A1 (ar) | 2017-03-29 | 2019-09-26 | Iovance Biotherapeutics Inc | عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي |
| EP3743063A4 (en) | 2018-01-26 | 2021-10-20 | Nurix Therapeutics, Inc. | CBL-B INHIBITORS AND THEIR METHODS OF USE |
| JP2021512059A (ja) | 2018-01-29 | 2021-05-13 | ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド | ブルトン型チロシンキナーゼ（ｂｔｋ）阻害剤のｅ３リガーゼリガンドとのコンジュゲーションによるｂｔｋの分解および使用方法 |
| KR20210040355A (ko) | 2018-06-19 | 2021-04-13 | 바이오엔테크 유에스 인크. | 네오항원 및 이의 용도 |
| EP3867242A1 (en) | 2018-10-15 | 2021-08-25 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading btk via ubiquitin proteosome pathway |
| EP3924350A1 (en) | 2019-02-13 | 2021-12-22 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading btk via ubiquitin proteosome pathway |
| KR102922115B1 (ko) | 2019-04-09 | 2026-02-04 | 누릭스 테라퓨틱스 인코포레이티드 | Cbl-b 억제용의 3-치환된 피페리딘 화합물, 및 암 백신 및/또는 종양용해 바이러스와 조합된 cbl-b 억제제의 용도 |
| CA3140873A1 (en) | 2019-05-17 | 2020-11-26 | Nurix Therapeutics, Inc. | Cyano cyclobutyl compounds for cbl-b inhibition and uses thereof |
| CA3294689A1 (en) | 2019-06-26 | 2026-03-02 | Nurix Therapeutics, Inc. | Substituted benzyl-triazole compounds for cbl-b inhibition, and further uses thereof |
| US12653809B2 (en) | 2019-07-30 | 2026-06-16 | Nurix Therapeutics, Inc. | Urea, amide, and substituted heteroaryl compounds for CBL-B inhibition |
| EP4034141A1 (en) | 2019-09-24 | 2022-08-03 | Nurix Therapeutics, Inc. | Cbl inhibitors and compositions for expansion of immune cells |
| WO2021091575A1 (en) | 2019-11-08 | 2021-05-14 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading btk via ubiquitin proteosome pathway |
| CN112812109B (zh) | 2019-11-18 | 2022-06-21 | 中国科学院微生物研究所 | 化合物DaP-01及其制备方法和应用 |
| CA3160713A1 (en) | 2019-12-04 | 2021-06-10 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading btk via ubiquitin proteosome pathway |
| EP4232023A4 (en) | 2020-10-26 | 2025-11-12 | Dana Farber Cancer Inst Inc | COMPOUNDS FOR THE TARGETED DEGRADATION OF KINASE PROTEINS |
| IL309796A (en) | 2021-07-14 | 2024-02-01 | Nurix Therapeutics Inc | Bifunctional compounds for BTK degradation with reduced IMID activity |
| EP4373493A1 (en) | 2021-07-23 | 2024-05-29 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading btk with enhanced imid activity |
| MX2024004899A (es) | 2021-10-26 | 2024-05-24 | Nurix Therapeutics Inc | Compuestos de piperidinilpirazina-carboxamida para tratar y prevenir el cancer y para degradar btk. |
| CN121548574A (zh) | 2023-04-28 | 2026-02-17 | 纽力克斯治疗公司 | 通过泛素蛋白酶体途径降解braf的双官能化合物 |
| CN122514523A (zh) | 2023-10-23 | 2026-08-04 | 纽力克斯治疗公司 | 双官能化合物的盐和游离碱及其多晶型物形式 |
-
2020
- 2020-12-03 CA CA3160713A patent/CA3160713A1/en active Pending
- 2020-12-03 AU AU2020397920A patent/AU2020397920B2/en active Active
- 2020-12-03 EP EP25161134.9A patent/EP4570320A3/en active Pending
- 2020-12-03 KR KR1020227022322A patent/KR102998007B1/ko active Active
- 2020-12-03 WO PCT/US2020/063176 patent/WO2021113557A1/en not_active Ceased
- 2020-12-03 HU HUE20829249A patent/HUE072392T2/hu unknown
- 2020-12-03 CN CN202080091041.XA patent/CN115003304A/zh active Pending
- 2020-12-03 EP EP20829249.0A patent/EP4069237B1/en active Active
- 2020-12-03 FI FIEP20829249.0T patent/FI4069237T3/fi active
- 2020-12-03 PL PL20829249.0T patent/PL4069237T3/pl unknown
- 2020-12-03 ES ES20829249T patent/ES3033520T3/es active Active
- 2020-12-03 BR BR112022010349A patent/BR112022010349A2/pt unknown
- 2020-12-03 IL IL293797A patent/IL293797A/en unknown
- 2020-12-03 DK DK20829249.0T patent/DK4069237T3/da active
- 2020-12-03 US US17/111,454 patent/US11820781B2/en active Active
- 2020-12-03 JP JP2022532148A patent/JP2023504147A/ja active Pending
- 2020-12-03 MX MX2022006672A patent/MX2022006672A/es unknown
-
2023
- 2023-03-10 US US18/120,341 patent/US12600732B2/en active Active
-
2025
- 2025-11-28 JP JP2025207457A patent/JP2026048713A/ja active Pending
-
2026
- 2026-02-27 US US19/552,781 patent/US20260193269A1/en active Pending
- 2026-07-21 AU AU2026207981A patent/AU2026207981A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024525797A5 (enExample) | ||
| JP2024526984A5 (enExample) | ||
| JP2018532737A5 (enExample) | ||
| JP2021529812A5 (enExample) | ||
| RU2376287C2 (ru) | Производные бензамида, способ их получения и их применение, фармацевтическая композиция и способ обеспечения ингибирующего действия по отношению к hdac | |
| HRP20241588T1 (hr) | Piridazinil tiazolekarboksamidni spoj | |
| JP2022520448A5 (enExample) | ||
| RU2460730C2 (ru) | Новые производные n-(8-гетероарилтетрагидронафталин-2-ил)-или n-(5-гетероарилхроман-3-ил)-карбоксамида для лечения боли | |
| CN105793261B (zh) | 吡唑并嘧啶化合物 | |
| JP2018138577A5 (enExample) | ||
| RU2007134396A (ru) | Химические соединения | |
| JP2020530838A5 (enExample) | ||
| JP2014051526A5 (enExample) | ||
| JP2014507455A5 (enExample) | ||
| RU2018112993A (ru) | Соединения и способы для ингибирования JAK | |
| JP2007534695A5 (enExample) | ||
| RU2011108281A (ru) | Трипиридилкарбоксамидные антагонисты орексиновых рецепторов | |
| JP2018517746A5 (enExample) | ||
| RU2018138828A (ru) | Уменьшение массы опухоли путем введения ccr1 антагонистов в комбинации с pd-1 ингибиторами или pd-l1 ингибиторами | |
| JP2020517598A5 (enExample) | ||
| RU2015143542A (ru) | Ингибиторы jak2 и alk2 и способы их использования | |
| RU2016150404A (ru) | Пирроло[2,3-с]пиридины в качестве визуализирующих агентов для нейрофибриллярных клубков | |
| JP2012500785A5 (enExample) | ||
| RU2012124811A (ru) | СПОСОБ ЛЕЧЕНИЯ ПРОЛИФЕРАТИВНЫХ НАРУШЕНИЙ И ДРУГИХ ПАТОЛОГИЧЕСКИХ СОСТОЯНИЙ, ОПОСРЕДОВАННЫХ АКТИВНОСТЬЮ КИНАЗ Bcr-Abl, c-Kit, DDR1, DDR2, ИЛИ PDGF-R | |
| NZ603654A (en) | Cyclopropane amides and analogs exhibiting anti-cancer and anti-proliferative activities |